DURABLE RESPONSE RATES THROUGH 5 YEARS1,2

Actor portrayal of SOTYKTU® patient in a blue shirt

POETYK PSO-1 AND PSO-2 STUDY DESIGNS

Superior response rates vs placebo at Week 16 (co-primary endpoints)3-5

PASI 75: PSO-1: 58% for SOTYKTU (n=330) vs 13% for placebo (n=166), P<0.0001; PSO-2: 53% for SOTYKTU (n=511) vs 9% for placebo (n=255), P<0.0001

sPGA 0/1: PSO-1: 54% (n=330) vs 7% for placebo (n=166), P<0.0001; PSO-2: 50% for SOTYKTU (n=511) vs 9% for placebo (n=255), P<0.0001

ADDITIONAL PIVOTAL TRIAL DATA

LTE STUDY DESIGN

In POETYK PSO-LTE

Durable PASI response rates through 5 years1

Post-hoc sub-analysis

PASI RESPONSE RATES WITH CONTINUOUS SOTYKTU TREATMENT IN PATIENTS ENTERING PSO-LTE1

Graphic showing PASI response rates through 5 years of SOTYKTU® POETYK PSO-1 and PSO-2 clinical trials

Data shown above are from PSO-LTE: pooled PSO-1 and PSO-2 through Week 256 (mNRI)1

LTE LIMITATION: In open-label LTEs, patients who lose response or are unable to tolerate treatment are likely to discontinue treatment, which may raise the proportion of responders in the overall population.

  • Data are derived from post-hoc sub-analysis of PSO-LTE and includes only patients from PSO-1 and PSO-2 who received continuous SOTYKTU from Day 1 (Week 0) and entered the LTE (n=513, entered; n=485, mNRI).1
Outcomes were analyzed descriptively
  • Note that the SOTYKTU arm of PSO-2 had forced re-randomization of half of the PASI 75 responders at Week 24; these patients are not included in this analysis, as they were no longer under continuous treatment1,3,6

Durable scalp response rates through 5 years2

Post-hoc sub-analysis

SS-PGA 0/1 RESPONSE RATES WITH CONTINUOUS SOTYKTU
USE IN PATIENTS ENTERING POETYK PSO-LTE

Graphic showing scalp response rates through 5 years of SOTYKTU® use

Data shown above are from PSO-LTE: pooled PSO-1 and PSO-2 through Week 244 (mNRI)

LTE LIMITATION: In open-label LTEs, patients who lose response or are unable to tolerate treatment are likely to discontinue treatment, which may raise the proportion of responders in the overall population.

  • Data are derived from post-hoc subanalysis of POETYK PSO-LTE and include only patients from POETYK PSO-1 and PSO-2 with ss-PGA ≥3 and who received continuous SOTYKTU from Day 1 (Week 0), and entered the LTE (n=317, entered; n=307, modified NRI). Outcomes were analyzed descriptively.
  • Note that the SOTYKTU arm of PSO-2 had forced re-randomization of half of the PASI 75 responders at Week 24; these patients are not included in this analysis, as they were no longer under continuous treatment.

LTE STUDY DESIGN1,6,7

POETYK PSO-LTE is an ongoing, open-label, long-term extension trial that enrolled participants from the phase 3 POETYK PSO-1 and PSO-2 trials. All patients in PSO-1 and PSO-2 were eligible to enter the LTE trial after 52 weeks of treatment, regardless of initial treatment. At the start of the LTE (Week 52), 1221 patients were blindly switched from SOTYKTU, apremilast, or placebo to open-label SOTYKTU 6 mg once daily. Primary endpoints are an incidence of adverse events and serious adverse events. Key secondary endpoints are sPGA 0/1 and PASI 75.

Data is presented as an interim analysis. Outcomes were analyzed descriptively.

ADDITIONAL PIVOTAL TRIAL DATA1,3,4

Select key secondary endpoints:

PASI 75

  • PASI 75 at Week 24 for SOTYKTU vs apremilast: PSO-1: 69% (n=228/330) vs 38% (n=64/168), P<0.0001; PSO-2: 58% (n=296/511) vs 38% (n=96/254), P<0.0001

PASI 90

  • PASI 90 at Week 16 for SOTYKTU vs apremilast: PSO-1: 36% (n=118/330) vs 20% (n=33/168), P=0.0002; PSO-2: 27% (n=138/511) and 18% for apremilast (n=46/254); P=0.0046. PASI 90 at Week 24 for SOTYKTU vs apremilast: PSO-1: 42% (n=140/330) vs 22% (n=37/168), P<0.0001; PSO-2: 32% (n=164/511) vs 20% (n=50/254), P=0.0002

ss-PGA 0/1

  • ss-PGA 0/1 at Week 16 for SOTYKTU vs apremilast†: PSO-1: 70% (n=147/209) vs 39% (n=43/110), P<0.0001; PSO-2: 60% (n=182/305) vs 37% (n=61/166), P<0.00018,9

†Included patients with a baseline ss-PGA score of ≥3.

LTE=long-term extension; mNRI=modified non-responder imputation; PASI=Psoriasis Area and Severity Index; PASI 75=≥75% improvement from baseline in PASI; PASI 90=≥90% improvement from baseline in PASI; ss-PGA=scalp-specific Physician's Global Assessment; ss-PGA 0/1=scalp-specific Physician's Global Assessment, patients achieving clear (0) or almost clear (1) skin.

ARE YOU READY TO EXPLORE MORE? SELECT A TOPIC BELOW.
References:
  1. Armstrong AW, Warren RB, Strober B, et al. Deucravacitinib in moderate to severe plaque psoriasis: 5-year, long-term safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at: Winter Clinical Dermatology Conference; February 14-19, 2025; Waikoloa, Hawaii.
  2. Armstrong AW, Warren RB, Strober B, et al. Deucravacitinib in moderate to severe plaque psoriasis: 5-year, long-term safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Poster presentation at: the Diversity in Dermatology Conference; March 27-30, 2025; Louisville, KY.
  3. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  4. Data on file. BMS-REF-DEU-0020. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  5. Data on file. BMS-REF-DEU-0021. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  6. Lebwohl M, Warren RB, Sofen H, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Br J Dermatol. 2024;190:668-679. doi:10.1093/bjd/ljae014
  7. ClinicalTrials.gov. NCT04036435. https://clinicaltrials.gov/ct2/show/NCT040364‌35‌. Accessed June 8, 2023.
  8. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29-39. doi:10.1016/j.jaad.2022.07.002
  9. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40-51. doi:10.1016/j.jaad.2022.08.061

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported. If a clinically significant hypersensitivity reaction occurs, institute appro‌p‌riate therapy and discontinue SOTYKTU.

Infections: SOTYKTU may increase the risk of infections. Serious infections have been reported in patients with psoriasis who received SOTYKTU. The most common serious infections reported with SOTYKTU included pneumonia and COVID-19. Avoid use of SOTYKTU in patients with an active or serious infection. Consider the risks and benefits of treatment prior to initiating SOTYKTU in patients:

  • with chronic or recurrent infection
  • who have been exposed to tuberculosis
  • with a history of a serious or an opportunistic infection
  • with underlying conditions that may predispose them to infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment. A patient who develops a new infection during treatment should undergo prompt and complete diagnostic testing, have appropriate antimicrobial therapy initiated and be closely monitored. Interrupt SOTYKTU if a patient develops a serious infection. Do not resume SOTYKTU until the infection resolves or is adequately treated.

Viral Reactivation

Herpes virus reactivation (e.g., herpes zoster, herpes simplex) was reported in clinical trials with SOTYKTU. Through Week 16, herpes simplex infections were reported in 17 patients (6.8 per 100 patient-years) treated with SOTYKTU, and 1 patient (0.8 per 100 patient-years) treated with placebo. Multidermatomal herpes zoster was reported in an immunocompetent patient. During PSO-1, PSO-2, and the open-label extension trial, the majority of patients who reported events of herpes zoster while receiving SOTYKTU were under 50 years of age. The impact of SOTYKTU on chronic viral hepatitis reactivation is unknown. Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting and during therapy with SOTYKTU. If signs of reactivation occur, consult a hepatitis specialist. SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C.

Tuberculosis (TB): In clinical trials, of 4 patients with latent TB who were treated with SOTYKTU and received appropriate TB prophylaxis, no patients developed active TB (during the mean follow-up of 34 weeks). One patient, who did not have latent TB, developed active TB after receiving 54 weeks of SOTYKTU. Evaluate patients for latent and active TB infection prior to initiating treatment with SOTYKTU. Do not administer SOTYKTU to patients with active TB. Initiate treatment of latent TB prior to administering SOTYKTU. Consider anti-TB therapy prior to initiation of SOTYKTU in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during treatment.

Malignancy including Lymphomas: Malignancies, including lymphomas, were observed in clinical trials with SOTYKTU. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with SOTYKTU, particularly in patients with a known malignancy (other than a successfully treated non-melanoma skin cancer) and patients who develop a malignancy when on treatment with SOTYKTU.

Rhabdomyolysis and Elevated CPK: Treatment with SOTYKTU was associated with an increased incidence of asymptomatic creatine phosphokinase (CPK) elevation and rhabdomyolysis compared to placebo. Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Instruct patients to promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

Laboratory Abnormalities: Treatment with SOTYKTU was associated with increases in triglyceride levels. Periodically evaluate serum triglycerides according to clinical guidelines during treatment. SOTYKTU treatment was associated with an increase in the incidence of liver enzyme elevation compared to placebo. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease according to routine management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt SOTYKTU until a diagnosis of liver injury is excluded.

Immunizations: Prior to initiating therapy with SOTYKTU, consider completion of all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination. Avoid use of live vaccines in patients treated with SOTYKTU. The response to live or non-live vaccines has not been evaluated.

Potential Risks Related to JAK Inhibition: It is not known whether tyrosine kinase 2 (TYK2) inhibition may be associated with the observed or potential adverse reactions of Janus Kinase (JAK) inhibition. In a large, randomized, postmarketing safety trial of a JAK inhibitor in rheumatoid arthritis (RA), patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. SOTYKTU is not approved for use in RA.

ADVERSE REACTIONS

Most common adverse reactions (≥1% of patients on SOTYKTU and more frequently than with placebo) include upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis and acne.

SPECIFIC POPULATIONS

Pregnancy: Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Report pregnancies to the Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072.

Lactation: There are no data on the presence of SOTYKTU in human milk, the effects on the breastfed infant, or the effects on milk production. SOTYKTU is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SOTYKTU and any potential adverse effects on the breastfed infant from SOTYKTU or from the underlying maternal condition.

Hepatic Impairment: SOTYKTU is not recommended for use in patients with severe hepatic impairment.

SOTYKTU is available in 6 mg tablets.

INDICATION

SOTYKTU® (deucravacitinib) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Limitations of Use:

SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

Please see U.S. Full Prescribing Information, including Medication Guide, for SOTYKTU.

  Bristol Myers Squibb® Logo

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
This site is intended for U.S. Healthcare Professionals only.
Otezla is a registered trademark of Amgen Inc.
© 2025 Bristol-Myers Squibb Company.

1787-US-2500022 09/25

Legal Notice    Privacy Policy    Your Privacy Choices Privacy Link    Sitemap